AMAG Pharma (AMAG) Reports Q3 Loss of $4.31/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
AMAG Pharma (AMAG) Reports Presentations of Hypophosphatemia Data From AMAG Phase 3 Trial
November 6, 2017 8:07 AM ESTAMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced data related to the occurrence of hypophosphatemia following intravenous (IV) iron treatment at a podium presentation at the 2017 American Society of Nephrology (ASN) annual meeting in New Orleans. The impact of the use of IV iron on phosphate metabolism was assessed as a secondary exploratory endpoint of the Phase 3 randomized, double-blind, non-inferiority clinical trial of Feraheme® (ferumoxytol) and Injectafer® (ferric carboxymaltose injection). This study was comprised of approximately 2,000 adult patients with iron deficiency anemia regardless of the cause who had failed or could not tolerate oral iron... More
AMAG Pharmaceuticals (AMAG) PT Lowered to $16; Remains Bullish
November 6, 2017 7:50 AM ESTJefferies lowered its price target on AMAG Pharmaceuticals (NASDAQ: AMAG) to $16.00 (from $34.00) while maintaining a Buy rating. Cheap valuation alone has not been enough to drive the stock in the absence of management execution. Instead, it's gotten cheaper.
For Makena, AMAG indicates >1 generics... More
AMAG Pharmaceuticals (AMAG) PT Lowered to $17 at Cantor Fitzgerald
November 2, 2017 1:23 PM EDTCantor Fitzgerald lowered its price target on AMAG Pharmaceuticals (NASDAQ: AMAG) to $17.00 (from $21.00) while maintaining a Neutral rating following Q3 results.
Analyst William Tanner said 2018 guidance unlikely until the dust settles.
... More